The National Institutes of Health released a study on November 5 showing a notable association between elevated blood concentrations of two common per‑ and polyfluoroalkyl substances (PFAS) — PFOA and PFOS — and increased rates of an aggressive form of breast cancer. Women in the highest exposure group had an estimated 67% higher rate of estrogen‑receptor‑negative (ER‑negative) breast cancer for PFOA and a 93% higher rate for PFOS compared with those in the lowest exposure group.
Study design and population
The research drew on data from the NIH‑funded Sister Study, which enrolled 50,884 women across the United States and Puerto Rico between 2003 and 2009. All participants had a full or half‑sister diagnosed with breast cancer but were cancer‑free at enrollment. For this analysis, investigators examined blood samples collected before any cancer diagnosis, measuring 17 PFAS chemicals.
The case‑cohort component included 1,609 breast cancer cases and a comparison sample of 2,269 participants, with some overlap of 114 women. Researchers oversampled ER‑negative tumors to strengthen that portion of the analysis, resulting in 324 ER‑negative and 1,120 ER‑positive cases.
Key findings
ER‑negative cancers lack the receptors that allow estrogen to drive tumor growth, typically leading to poorer outcomes than ER‑positive cancers. The NIH team found no clear link between PFOA or PFOS and overall breast cancer incidence, nor with ER‑positive tumors. However, the elevated rates for ER‑negative disease were statistically significant for both chemicals.
When the investigators combined their new data with earlier studies that measured PFAS exposure before cancer diagnosis, the meta‑analysis produced a pooled relative risk of 1.30 for PFOA and ER‑negative cancer. The pooled estimate for PFOS was 1.20, but its confidence interval (0.91‑1.58) crossed 1.0, leaving that result uncertain.
Limitations and context
Because the study is observational, it cannot establish that PFAS caused the tumors. The researchers adjusted for age, reproductive history, body‑mass index, smoking, alcohol use, and other PFAS exposures, yet residual confounding remains possible. Additionally, the Sister Study recruited women with a family history of breast cancer, which may limit the applicability of the findings to the broader population.
The timing of the announcement coincided with 3M’s recent $7.35 billion settlement of PFAS‑related personal‑injury claims, though breast cancer was not listed among the covered conditions. Texas also sued 3M and related companies in 2024 over alleged misleading marketing of PFAS‑containing consumer products.
Regulatory backdrop
The Environmental Protection Agency currently sets a federal drinking‑water limit of 4 parts per trillion for each chemical. Residents are encouraged to review their water provider’s testing results and consider certified filtration systems that reduce PFAS levels. In May, the EPA proposed allowing eligible water systems to request an extension of the current limit until 2031, without altering the 4‑ppt standard.
Next steps
Researchers called for additional studies focusing on highly exposed populations and newer replacement chemicals. They emphasized that the present findings do not demonstrate that any specific water‑filter technology prevents breast cancer.
Overall, the NIH study adds to a growing body of evidence linking PFAS exposure to certain health risks, underscoring the need for continued monitoring, transparent reporting, and responsible stewardship of our water resources.
Original reporting: The Dallas Express — read the source article.
